Neurology
Page 1 • 12 itemsGain critical insights into global neurology drug development, clinical trials, regulatory approvals, and market trends. Inform your pharma strategy.
Vanda Pharmaceuticals Launches NEREUS (Tradipitant) - First New Motion Sickness Drug in 40+ Years Now Available
Vanda Pharmaceuticals announces commercial availability of NEREUS (tradipitant), the first new prescription motion sickness treatment in over 40 years.
GRIN Therapeutics Expands Phase 3 Beeline Study for Radiprodil to Europe for GRIN-NDD Treatment
GRIN Therapeutics initiates Phase 3 Beeline study in Europe for investigational radiprodil targeting GRIN-NDD, expanding global clinical program.
Stoke Therapeutics Zorevunersen Shows Promise for Dravet Syndrome Treatment Ahead of Q1 2026 Results
Stoke Therapeutics prepares Q1 2026 earnings call featuring Zorevunersen, an investigational antisense therapy targeting Dravet syndrome's underlying cause.
uniQure AMT-130 Gene Therapy Advances Toward UK Approval for Huntington's Disease Treatment
uniQure completes successful UK MHRA pre-submission meeting for AMT-130 Huntington's disease gene therapy, targeting Q3 2026 marketing authorization application.
SetPoint Medical Begins Multiple Sclerosis Trial for Setpoint System Neuroimmune Therapy
SetPoint Medical enrolls first patients in pilot study testing Setpoint System for relapsing-remitting multiple sclerosis treatment with FDA approval.
Telix Pharmaceuticals' TLX101-Px (Pixlumi) Brain Cancer Imaging Drug Accepted for European Review
Telix Pharmaceuticals' TLX101-Px (Pixlumi) glioma imaging drug enters 210-day European regulatory review after MAA acceptance, targeting brain cancer diagnosis.
Ray Therapeutics RTx-015 Receives EMA PRIME Designation for Retinitis Pigmentosa Treatment
Ray Therapeutics' RTx-015 gene therapy receives EMA PRIME designation for retinitis pigmentosa, accelerating regulatory pathway for vision restoration treatment.
Idorsia Reports 74% QUVIVIQ Sales Growth in Q1 2026, Expands European Market Reach
Idorsia's insomnia drug QUVIVIQ achieves 74% year-over-year sales growth in Q1 2026, with European expansion and pediatric data driving future growth.
Solid Biosciences Receives European Orphan Drug Designation for SGT-003 Duchenne Muscular Dystrophy Treatment
Solid Biosciences secures European Commission orphan drug designation for SGT-003, advancing gene therapy development for Duchenne muscular dystrophy patients.
EMA Issues Positive Opinion for Itvisma (Onasemnogene Abeparvovec) Gene Therapy for Spinal Muscular Atrophy
European Medicines Agency issues positive opinion for Itvisma, a one-time gene therapy for spinal muscular atrophy in infants and children.
EMA Issues Positive Opinion for Cenrifki (Tolebrutinib) Multiple Sclerosis Treatment
European Medicines Agency issues positive opinion for Cenrifki (tolebrutinib), a potential new oral treatment for multiple sclerosis patients.
CervoMed's Neflamapimod Shows Brain Volume Increase in Dementia with Lewy Bodies Trial at AAN 2026
CervoMed reports neflamapimod increased basal forebrain volume and connectivity in DLB patients, suggesting potential disease reversal in early stages.